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Abstract
Background: Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant
prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone
metastases are lacking.
Methods: This was a prospective, single-arm phase 3b study. Patients with metastatic CRPC (malignant lymphadenopathy
not exceeding 6 cm was allowed, visceral disease was excluded) received radium-223, 55 kBq/kg intravenously, every 4
weeks for up to 6 cycles. Co-primary endpoints were safety and overall survival. Post hoc analyses were performed
according to baseline asymptomatic or symptomatic disease status. Asymptomatic status was defined as no pain and no
opioid use at baseline.
Results: Seven hundred eight patients received ≥1 radium-223 injection: 548 (77%) were symptomatic to various
degrees, and 135 (19%) were asymptomatic. Asymptomatic patients had more favorable baseline disease characteristics
than symptomatic. A lower proportion of asymptomatic versus symptomatic patients had received prior abiraterone
(25% vs 35%) and prior docetaxel (52% vs 62%). A higher proportion of asymptomatic (71%) versus symptomatic (55%)
patients completed radium-223 treatment. Overall survival (hazard ratio [HR] 0.486), time to disease progression (HR 0.
722) and time to first symptomatic skeletal event (HR 0.328) were better in asymptomatic than symptomatic patients.
Alkaline phosphatase (ALP) response rates were similar (46% vs 47%), and ALP normalization (44% vs 25%) and
prostate-specific antigen response rates (21% vs 13%) were higher in asymptomatic than symptomatic patients. A
lower proportion of asymptomatic patients reported treatment-emergent adverse events (TEAEs, 61% vs 79%), grade
3–4 TEAEs (29% vs 40%) and drug-related TEAEs (28% vs 44%). There were two treatment-related deaths, both in
patients with baseline symptomatic disease.
Conclusions: Using radium-223 earlier in the disease course, when patients are asymptomatic or minimally
symptomatic, may enable patients to complete treatment and optimize treatment outcome compared to symptomatic
patients, and therefore may allow sequencing with other life-prolonging therapies.
Trial registration: The study was registered with ClinicalTrials.gov, number NCT01618370 on June 13, 2012 and the
European Union Clinical Trials Register, EudraCT number 2012–000075-16 on April 4, 2012.
Keywords: Radium-223, mCRPC, asymptomatic, Symptomatic, Bone metastases
* Correspondence: axel.heidenreich@uk-koeln.de
1Department of Urology, University Hospital Cologne, Cologne, Germany
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Heidenreich et al. BMC Cancer           (2019) 19:12 
https://doi.org/10.1186/s12885-018-5203-y
Background
Radium-223 dichloride (radium-223), a targeted alpha ther-
apy, is incorporated into newly formed bone in areas of
osteoblast activity and increased bone turnover sur-
rounding prostate cancer bone metastases [1, 2].
Radium-223 emits high energy alpha particles over a
short range resulting in a localized potent antitumor
effect and inhibition of tumor-induced osteoblastic ac-
tivity in preclinical models [3].
Radium-223 is recommended for the treatment of pa-
tients with mCRPC and symptomatic bone metastases
[4, 5]. In the pivotal phase 3 ALSYMPCA study, patients
with mCRPC and symptomatic bone metastases assigned
to radium-223 with best standard of care (BSoC) dem-
onstrated prolonged overall survival (median 14.0 vs
11.2 months, hazard ratio [HR] 0.70; 95% CI, 0.58–0.83;
p < 0.001) and delayed time to first symptomatic skeletal
event (SSE) compared with those assigned to placebo
with BSoC [6, 7]. Radium-223 was generally well toler-
ated and improvements in patient quality of life were
reported compared with patients treated in the placebo
arm [6, 8].
In the phase 3 study patients with symptomatic bone
metastases were defined as those who regularly used anal-
gesic medication (opioids or non-opioids were allowed),
or those who were pain-free, but had received external
beam radiation therapy (EBRT) for cancer-related bone
pain within a 12 week period before enrollment [6]. How-
ever, patients with mCRPC and bone predominant disease
often initially present without symptoms [9] and data for
radium-223 in these patients are lacking.
Data from clinical trials investigating life-prolonging
agents have shown that treating patients with mCRPC
earlier in their disease course, for example those who
are mildly symptomatic or asymptomatic, can be benefi-
cial. In the TAX 327 study docetaxel every 3 weeks
compared with mitoxantrone demonstrated an overall
survival benefit (HR 0.76) in patients with mCRPC,
which was also demonstrated in a subgroup analysis of
patients without pain at baseline (HR 0.73) [10]. Andro-
gen receptor axis-targeted agents, abiraterone acetate
(abiraterone, HR 0.65) [11] and enzalutamide (HR 0.63)
[12], provided a significant survival benefit in compari-
son with placebo in patients with mCRPC progressing
on docetaxel. A similar overall survival benefit was
reported in subgroup analyses of patients with no clinic-
ally significant baseline pain (abiraterone HR 0.64, and
enzalutamide HR 0.59). Moreover, abiraterone (HR 0.81)
and enzalutamide (HR 0.71) demonstrated a survival ad-
vantage over placebo when administered first-line in
asymptomatic or mildly symptomatic patients with
mCRPC [13, 14]. Similarly, it may also be the case that
radium-223 is beneficial to patients with asymptomatic
bone predominant metastases.
In a phase 3b international early access program
(iEAP), patients with asymptomatic mCRPC were in-
cluded [15], which enabled the current analysis investi-
gating the safety and activity of radium-223 in this
patient population.
Methods
Study design and treatment
Study design and patient inclusion and exclusion criteria
for this phase 3b study have been previously reported in de-
tail [15]. Patients were ≥ 18 years or older, had histologically
or cytologically confirmed progressive bone-predominant
mCRPC with two or more skeletal metastases on imaging
(symptomatic or asymptomatic), and no visceral disease
(lymph node-only metastases not exceeding 6 cm were
allowed) [15].
Patients were treated with intravenous injections of
radium-223, 55 kBq/kg, every 4 weeks for up to 6 cycles
[15]. Concomitant treatment was permitted including
abiraterone or enzalutamide, and bone supportive agents
as previously described [15]. Supportive care was deliv-
ered according to local institutional guidelines [15].
Study assessments
Primary endpoints were safety and overall survival.
Symptomatic disease was defined as having pain, or
using opioids for cancer related pain at baseline. Asymp-
tomatic disease was defined as no pain (Brief Pain Inven-
tory Short Form [BPI-SF] score of 0) and no opioid use
at baseline (use of non-opioid analgesics was allowed).
Pain severity was assessed using the self-administered vali-
dated BPI-SF questionnaire as previously described [15].
Exploratory efficacy variables included time from start of
therapy to first SSE, time to disease progression, and alka-
line phosphatase (ALP) response and normalization and
prostate specific antigen (PSA) response.
SSEs were defined as the use of EBRT to relieve skel-
etal symptoms, or the occurrence of new symptomatic
pathological bone fractures (vertebral or non-vertebral),
or the occurrence of spinal cord compression, or a
tumor-related orthopedic surgical intervention. Time to
first SSE was defined as time in months from the start of
radium-223 until occurrence of the first SSE during the
study period. Time to disease progression was defined as
the time in months from the start of radium-223 to the
date that disease progression (including radiographic,
clinical and PSA progression) was assessed as per the
local standard of care. Total-ALP and PSA responses,
and ALP normalization, were defined as previously re-
ported [15]. Specifically responses were defined as ≥30%
reduction of the blood level, compared to the baseline
value, confirmed by a second value obtained approxi-
mately 4 or more weeks later. Total-ALP normalization
was defined as the return of the total-ALP value to
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within the normal range at 12 weeks after the start of
treatment, based on 2 consecutive measurements (at
least 2 weeks apart), in patients who had their total-ALP
above the upper limit of normal (ULN) at baseline [15].
Adverse events were coded using the Medical Diction-
ary for Regulatory Activities (MedDRA) version 17.1 and
graded using the Common Terminology Criteria for Ad-
verse Events version 4.03, as previously reported [15].
Treatment-emergent adverse events (TEAEs) were de-
fined as those occurring on or after the date and time of
administration of the first dose of study drug, or if they
were present prior to the administration of the first dose
of study drug and increased in severity during the study.
Statistics
Exploratory safety and efficacy analyses were performed
in patients who had received at least one dose of study
drug and for whom symptom status at baseline could be
defined. Kaplan-Meier methodology was used to estimate
time-to event data. HRs were calculated using a Cox
regression model [15]. The HR (asymptomatic vs symp-
tomatic) was calculated using a Cox regression model.
Results
Patients
In this updated analysis of the iEAP, 708 patients re-
ceived at least one radium-223 injection, of whom 683
patients could be defined by symptom status at baseline;
135 (19%) were asymptomatic and 548 (77%) were
symptomatic. Twenty-five (4%) patients were excluded
from the analysis as symptom status could not be con-
firmed for reasons including missing baseline pain scores
or use of opioids for non-cancer-related pain. Of the
asymptomatic patients, 19/135 (14%) only reported use
of non-opioid analgesics at baseline.
Patients who were asymptomatic had more favorable
baseline characteristics than those who were symptom-
atic, including Eastern Cooperative Oncology Group
performance status (ECOG PS), lower PSA levels and
longer time to metastases from initial diagnosis of pros-
tate cancer (Table 1). A lower proportion of patients
who were asymptomatic compared with symptomatic
had received prior abiraterone (25% vs 35%) and prior
docetaxel (52% vs 62%). A higher proportion of patients
who were asymptomatic (71%) compared with symptom-
atic (55%) received all 6 planned cycles of radium-223
(Table 2). The most common reasons for treatment dis-
continuation in symptomatic (156/248, 63%) compared
with asymptomatic (17/39, 43%) patients were those as-
sociated with disease progression [see Additional file 1].
During the treatment period for radium-223, comparing
asymptomatic with symptomatic patients, 21% vs 16%
were treated with concomitant abiraterone, 6% vs 5% with
Table 1 Baseline characteristics in radium-223 treated patients
according to symptom status
Characteristics Asymptomatic
N = 135
Symptomatic
N = 548
Age, median (range), years 73.0 (51.0–91.0) 72.0 (45.0–94.0)
Race, white 133 (99) 534 (97)
ECOG PS
0 76 (56) 176 (32)
1 52 (39) 293 (53)
≥2 7 (5) 79 (14)
Combined Gleason score at initial diagnosis
2–4 2 (1) 13 (2)
5–7 54 (40) 209 (38)
8–10 67 (50) 277 (51)
Missing 12 (9) 49 (9)
Alkaline phosphatase,a U/L
Median (range) 127.0 (19.0–1349.0) 168.0 (22.0–4236.0)
Prostate specific antigen,b μg/L
Median (range) 113.0 (0–3266.0) 154.6 (0–12,150.0)
Hemoglobin g/dL
Median (range) 12.8 (8.7–15.8) 12.1 (8.4–18.0)
Time between initial diagnosis of prostate cancer and bone
metastasis,c months
Median (range) 30.2 (0–237.7) 13.6 (0–252.2)
Prior use of bone supportive agents
Bisphosphonates 11 (8) 35 (6)
Denosumab 4 (3) 10 (2)
Prior use of anticancer agents
Docetaxel 70 (52) 339 (62)
Abiraterone 34 (25) 190 (35)
Enzalutamide 5 (4) 43 (8)
Data are number of patients (%) unless stated otherwise
aAsymptomatic, n = 133; symptomatic, n = 545
bAsymptomatic, n = 134; symptomatic, n = 543
cAsymptomatic, n = 87; symptomatic, n = 543
ECOG PS Eastern Cooperative Oncology Group performance status
Table 2 Number of radium-223 injections received according to
symptom status
Radium-223 injections Asymptomatic N = 135 Symptomatic N = 548
Median (range) 6 (1–6) 6 (1–6)
Only 1 4 (3) 33 (6)
Only 2 3 (2) 40 (7)
Only 3 5 (4) 59 (11)
Only 4 13 (10) 59 (11)
Only 5 14 (10) 57 (10)
All 6 96 (71) 300 (55)
Data are number of patients (%) unless stated otherwise
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enzalutamide, 18% each with bisphosphonates, and 19% v
18% with denosumab concomitantly.
Efficacy
Median follow-up was 9.8 months for both asymptom-
atic patients (95% CI 8.5–10.9) and for symptomatic pa-
tients (95% CI 9.2–10.5). High censoring rates were
noted for overall survival and time to first SSE analyses
due to the short follow-up time of the trial. Longer
medians for overall survival (Fig. 1) and time to disease
progression (Fig. 2) were observed in asymptomatic
patients compared with those who were symptomatic.
HRs of 0.486 (Fig. 1) and 0.722 (Fig. 2) indicated that
the risk of death or disease progression was lower by 51
and 28% respectively in the asymptomatic compared
with the symptomatic group.
During the study period, SSEs were recorded in 13/
135 (10%) patients who were asymptomatic compared
with 130/548 (24%) who were symptomatic at baseline
[see Additional file 2]. Median time to first SSE was not
reached in either of the two groups. The HR of 0.328
indicated that the risk of a SSE was lower by 67% in
the asymptomatic compared with the symptomatic
group (Fig. 3).
Total-ALP responses [see Additional file 3] were simi-
lar in asymptomatic (62/135, 46%) and symptomatic
patients (259/548, 47%), as were total-ALP responses in
those patients with baseline levels above the ULN (43/
71, 61% vs 212/342, 62%). For patients with total-ALP
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Censored patients, n (%) 108 (80) 356 (65)
Median overall survival (95% CI), months 20.5 (20.5–NR) 13.5 (11.7–17.1)
Hazard ratio (95% CI) 0.486 (0.325–0.728)
NR=not reached
Fig. 1 Overall survival in radium-223 treated patients according to symptom status at baseline
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levels above the ULN at baseline, total-ALP was more
often returned to the normal range in asymptomatic
patients (31/71, 44%) compared with symptomatic pa-
tients (86/342, 25%).
The PSA response rate [see Additional file 4] was
higher in asymptomatic (29/135, 21%) compared with
symptomatic patients (72/548, 13%), as was the PSA re-
sponse rate in those patients with baseline PSA levels
above the ULN (28/129, 22% vs 65/514, 13%).
Safety
A lower proportion of asymptomatic patients (82/135,
61%) reported TEAEs compared with symptomatic
patients (435/548, 79%) (Table 3). The most common
grade 3–4 TEAEs (≥3% in either subgroup) in asymp-
tomatic vs symptomatic patients were anemia, 6 (4%) vs
73 patients (13%), thrombocytopenia 2 (1%) vs 22 (4%)
back pain 1 (< 1%) vs 19 (3%), bone pain, 3 (2%) vs 26
(5%) and spinal cord compression 0 vs 19 (3%) TEAEs
considered to be related to treatment were reported in
38 (28%) asymptomatic patients and 243 (44%) symp-
tomatic patients [see Additional file 5]; the most com-
mon grade 3–4 adverse event related to treatment was
anemia in 3 (2%) vs 28 (5%) patients respectively. Ser-
ious adverse events were reported in 30 (22%) patients
with asymptomatic and 210 (38%) patients with symp-
tomatic disease, which in 2 (1%) and 31 patients (6%)
respectively were considered to be treatment-related.
Adverse events leading to permanent discontinuation
were reported in 21 (16%) patients with asymptomatic
disease and 123 (22%) with symptomatic disease: in 6
(4%) and 33 (4%) patients respectively they were consid-
ered to be related to treatment. Adverse events leading
to death were reported in 2 (< 1%) asymptomatic patients
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Median time to disease progression (95% CI), 
months
6.9 (5.8–10.6) 5.7 (5.4–6.0)
Hazard ratio (95% CI) 0.722 (0.563–0.927)
Fig. 2 Time to disease progression in radium-223 treated patients according to symptom status at baseline
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(1 cardiac failure and 1 sepsis) and 32 (6%) symptomatic
patients (most commonly due to general physical health
deterioration in 12 patients). Two TEAEs leading to death
were considered to be treatment-related, both in symp-
tomatic patients (1 patient with neutropenia, and 1 with
an intestinal perforation).
Discussion
Some clinicians would consider treating patients with
mCRPC and asymptomatic disease with radium-223 in
their current clinical practice [16]. It may be that admin-
istering radium-223 to patients earlier in their disease
course, before the onset of severe symptoms and patient
clinical deterioration, would lead to improved outcomes.
In this iEAP, the safety profile of radium-223 appeared
to be better in patients with asymptomatic mCRPC
compared with symptomatic disease, with no unex-
pected adverse events reported in either group. This in-
cluded fewer TEAEs that were considered to be related
to treatment in the asymptomatic group, despite a
higher proportion of patients completing 6 radium-223
cycles compared with symptomatic patients. Clinical
outcome was also better in radium-223 treated patients
with asymptomatic disease who experienced longer over-
all survival, longer time to disease progression, and a
lower risk of SSEs during the study compared with those
treated with radium-223 with symptomatic disease.
Furthermore, whilst ALP response was similar be-
tween the groups, a higher proportion of asymptom-
atic patients experienced ALP normalization, and PSA
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CI), months
NR (NR) NR (17.5–NR)
Hazard ratio (95% CI) 0.328 (0.185–0.580)
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Fig. 3 Time to first symptomatic skeletal event in radium-223 treated patients according to symptom status at baseline
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responses, compared with symptomatic patients treated
with radium-223. Changes in PSA levels are not consid-
ered to be a reliable maker for monitoring radium-233
efficacy in this setting [17]. The current findings of a
higher PSA response in patients with asymptomatic bone
metastases require validation and further investigation in
prospective studies.
In the ALSYMPCA study, 513 out of 921 (56%) ran-
domly assigned patients had recorded opioid use at base-
line (345 assigned to radium-223 and 168 to placebo). In a
subgroup analysis, radium-223 compared with placebo
improved overall survival and reduced the risk of initial
SSEs during the study, regardless of baseline opioid use
[18]. Indeed, radium-223 appeared to be more effective in
delaying SSEs in the minimally symptomatic (WHO
ladder pain score 0–1) patients who did not require
opioid use at baseline (HR: 0.56, 95% CI: 0.39–0.82)
compared with those patients with more advanced
symptomatic disease (WHO ladder pain score 2–3)
who required baseline opioid therapy (HR: 0.72, 95%
CI: 0.53–0.98). Furthermore compared with placebo,
radium-223 prolonged time to first opioid use and
EBRT for pain in the non-opioid group of patients.
Radium-223 was well tolerated in patients irrespective
of their opioid use at baseline. The authors concluded
that pain symptom severity should not be the basis
for determining appropriate timing of radium-223
treatment [18].
In this iEAP, patients with asymptomatic disease had
more favorable baseline factors that are associated with
good prognosis [15, 19, 20], including lower median
ALP and PSA levels and lower ECOG PS, suggesting
that they had generally less advanced disease than those
who had symptoms. Further, the longer time between
cancer diagnosis and appearance of bone metastases
recorded in the asymptomatic patients may be indicative
of a slower disease course in this subgroup of patients.
In a separate post hoc analysis of the iEAP, the likeli-
hood of completing radium-223 treatment (receiving 5–
6 radium-223 injections) was increased in patients with
more favorable prognostic factors at baseline (less pain,
low ECOG PS, low PSA level and high hemoglobin level)
[21]. In the analysis, overall survival was reported to be
longer in patients who received 5–6 injections of
radium-223 compared with those who discontinued
radium-223 early (received only 1–4 injections of
radium-223) [21]. Similar findings were reported from a
post hoc analyses of a US EAP and the ALSYMPCA
study [22].
Patients treated in this iEAP were generally similar to
those currently treated in routine clinical practice, and
included chemotherapy-naïve patients, and those who
Table 3 Treatment emergent adverse events in radium-223 treated patients according to symptom status
Adverse eventsa Asymptomatic N = 135 Symptomatic N = 548
Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Any 41 (30) 39 (29) 185 (34) 218 (40)
Anemiab 12 (9) 6 (4) 64 (12) 72 (13)
Neutropeniac 1 (< 1) 5 (4) 7 (1) 9 (2)
Thrombocytopeniad 5 (4) 2 (1) 25 (5) 22 (4)
Constipation 2 (1) 0 23 (4) 6 (1)
Diarrhea 15 (11) 0 59 (11) 4 (< 1)
Nausea 15 (11) 0 74 (14) 1 (< 1)
Vomiting 6 (4) 0 27 (5) 7 (1)
Asthenia 1 (< 1) 0 22 (4) 2 (< 1)
Fatigue 14 (10) 1 (< 1) 39 (7) 12 (2)
General physical health deterioration 0 2 (1) 7 (1) 12 (2)
Weight decreased 9 (7) 1 (< 1) 34 (6) 5 (< 1)
Decreased appetite 10 (7) 0 34 (6) 2 (< 1)
Arthralgia 1 (< 1) 1 (< 1) 20 (4) 1 (< 1)
Back pain 5 (4) 1 (< 1) 24 (4) 19 (3)
Bone pain 8 (6) 3 (2) 75 (14) 26 (5)
Spinal cord compression 0 0 3 (< 1) 19 (3)
Data are number of patients (%) reported in ≥3% in either group and ordered as MedDRA system organ class and preferred terms. Grade 5 TEAEs were reported
in 2 (1%) asymptomatic and 32 (6%) symptomatic patients. aReported as MedDRA preferred terms during the treatment period. Combined MedDRA preferred
terms: banemia and hemoglobin decreased; cneutropenia and neutrophil count decreased; dthrombocytopenia and platelet count decreased. MedDRA, Medical
Dictionary for Regulatory Activities
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had previously received or were receiving concomitant
treatment with abiraterone or enzalutamide [15]. This
contrasts with the ALSYMPCA study where patients
previously treated with chemotherapy or those who were
ineligible for chemotherapy treatment were recruited,
but at the time of the ALSYMPCA study abiraterone
and enzalutamide were investigational agents and were
therefore unavailable [6].
During the treatment period, comparing asymptom-
atic with symptomatic patients, 21% vs 16% were
treated with concomitant abiraterone and 6% vs 5%
with concomitant enzalutamide respectively. It is im-
portant to note that concomitant treatment of these
patients with radium-223 and new hormonal agents
may have affected the outcome observed [15]. As
similar proportions of asymptomatic vs symptomatic
patients received concomitant abiraterone or enzaluta-
mide, we believe that concomitant treatment alone is
unlikely to account for the difference in overall sur-
vival (medians 20.5 vs 13.5 months) observed between
these patient groups.
A phase 3 randomized, double-blind study of radium-
223 or placebo, each in combination with abiraterone
plus prednisone in chemotherapy-naive patients with
asymptomatic or mildly symptomatic mCRPC with bone
metastases (ERA 223; NCT02043678) was recently pre-
maturely unblinded. The independent data monitoring
committee recommended unblinding the trial due to the
observation of more fractures and deaths in the combin-
ation treatment arm. Given these results from the ERA
223 trial, the current recommendation is not to combine
radium-223 with concomitant abiraterone acetate and
prednisone in this asymptomatic patient population [23].
The phase 3 PEACE III trial evaluating radium-223 in
combination with enzalutamide versus enzalutamide
alone, in patients with mildly symptomatic or asymp-
tomatic mCRPC, is ongoing.
In this single-arm iEAP, the association between symp-
toms and overall survival confirms the prognostic value
of patient symptoms at baseline. Using radium-223
earlier in the disease course, when patients are asymp-
tomatic or minimally symptomatic, may enable patients
to complete treatment and optimize treatment outcome
compared to symptomatic patients, and therefore may
allow sequencing with other life-prolonging therapies.
Conclusion
In conclusion, use of radium-223 in this group of 135
asymptomatic patients seems to be safe in the setting of
this iEAP, however, caution is still warranted in daily clin-
ical practice, as the subgroup size from this study was
small, the drug is not approved in this setting, and the
final results of prospective studies have to be awaited.
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Hafia (TU 39003); Assaf Harofeh Medical Center Ethics Committee, Zrifin (TU
39004); Hadassah Hebrew University Hospital Ein Kerem Helsinki Committee,
Hadassah University Medical Center, Jerusalem (TU 39005); Rabin Medical
Center - Beilinson Campus Ethics Committee, Petah Tikva (TU 39006); Tel-
Aviv Sourasky Medical Center Ethics Committee, Tel-Aviv (TU 39007); Chaim
Sheba Medical Center Ethics Committee, Ramat Gan (TU 39009). Italy: IRST
Istituto Scientifico Romagnolo per studio e cura Tumori CE IRST IRCCS-AVR:
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Ethikkommission Aargau, Departement Gesundheit und Soziales, Aarau (TU
58004); Ethikkommission NordWest- und Zentralschweiz, Basel (TU 58005);
Kantonale Ethikkommission Bern – KEK Institut für Pathophysiologie, Bern (TU
58007); Commission cantonale d’éthique de la recherche CCER, Genève (TU
58009). United Kingdom: National Research Ethics Service (NRES) Committee
South West – Central Bristol South West Research Ethics Committee Centre,
Bristol (TU 12006, 12,011, 12,015, 12,019, 12,020, 12,021, 12,024, 12,026).
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